Nimodipine Capsules Rx
Generic Name and Formulations:
Nimodipine 30mg; soft-gel caps.
Various generic manufacturers
Indications for Nimodipine Capsules:
To improve neurological outcome of subarachnoid hemorrhage from ruptured intracranial berry aneurysms, regardless of post-ictus neurological condition.
Take on empty stomach. 60mg every 4 hours for 21 consecutive days. Start within 96 hours of subarachnoid hemorrhage. If oral therapy is not feasible, may extract capsule contents into a syringe and give via in situ NG tube, then flush tube with normal saline. Hepatic impairment: 30mg every 4 hours; monitor.
Not for IV or other parenteral administration (may be fatal). Hepatic impairment. Monitor BP, heart rate. Pregnancy (Cat.C). Nursing mothers: not recommended.
Calcium channel blocker (CCB).
May potentiate other calcium channel blockers. Potentiated by cimetidine.
Decreased blood pressure, GI upset, headache, bradycardia, flushing, edema, rash; rare: intestinal pseudo-obstruction and ileus.
Formerly known under the brand name Nimotop.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness